Taiga Initiates Phase 1/2 Clinical Study of TBX-2400 in Acute Myeloid Leukemia and Myelofibrosis in Croatia

TBX-2400 is expected to improve engraftment and reconstitution of immune system for patients receiving Hematopoietic Stem Cell Transplants.